Mushrooms Inc (ID) (MSRM)

I am buying some back here...just in case they continue the mushroom approach with these fantastic developments trickling in

I like this news. this part especially.
Investor Interest
In connection with its continued development and upcoming validation initiatives, the Company is evaluating opportunities to engage with accredited investors interested in participating in the next phase of MycoLabX’s growth.

$MSRM Mushrooms Inc. (OTC: MSRM) Achieves Proof of Concept for MycoLabX Infection-Detection Technology and Provides Strategic Update

https://www.globenewswire.com/news-release/2026/03/24/3261383/0/en/Mushrooms-Inc-OTC-MSRM-Achieves-Proof-of-Concept-for-MycoLabX-Infection-Detection-Technology-and-Provides-Strategic-Update.html

ESTERO, Fla., March 24, 2026 (GLOBE NEWSWIRE) -- Mushrooms Inc. (OTC: MSRM) today announced the successful early-stage validation of its mycelium-based infection detection technology and the completion of beta testing for its MycoLab.ai research platform, marking a significant advancement in the development of its MycoLabX platform. These milestones strengthen the company’s position in emerging fungal biotechnology and biomaterials innovation and have led the company to reassess its strategic options and the structure of the previously announced strategic transaction with SecurCapital Corp.

Technology Milestone and Patent Section
Over the past weeks, MycoLabX has achieved an important technical milestone in collaboration with the company’s research team in Germany. Prototype testing successfully demonstrated a visible color-change response when the company’s mycelium-based films were exposed to bacterial activity, confirming the core sensing mechanism underlying the company’s infection-detection biomaterials platform.

This milestone represents successful early-stage proof of concept, validating the foundational biological response central to the company’s patent-pending technology.

The observed biological response supports the company’s approach, which utilizes engineered mycelium-derived biomaterials designed to react to bacterial presence and provide a visual indication of infection.

Following this initial validation, the company is preparing for the next phase of development, which is expected to include expanded testing and third-party validation initiatives, including evaluation pathways with leading U.S. research and defense-related institutions.

This successful early validation represents a key milestone toward the development of next-generation biomaterials capable of detecting infection in wound care, medical monitoring, and related healthcare applications. The company believes such technologies may ultimately support future regulatory pathways applicable to biomedical sensing and wound-monitoring devices.

The intellectual property covering these technologies is currently under review with the United States Patent and Trademark Office as part of the company’s ongoing patent application process.

These developments have contributed to a reassessment of the company’s strategic positioning and the potential value of the MycoLabX platform.

Management believes the successful demonstration of this core mechanism, combined with planned next-phase validation, represents a meaningful advancement toward commercialization and significantly enhances the platform’s long-term value potential.

These recent scientific developments significantly expand the potential value and strategic direction of the MycoLabX platform and support the company’s continued investment in advancing the technology through additional validation and development phases.

MYCOLab.ai Platform
In addition, the MycoLab.ai mycology research platform has successfully completed beta testing, demonstrating the effectiveness of its AI-driven interface in accessing and organizing foundational scientific data within the platform.

MycoLab.ai is a proprietary, structured research environment focused exclusively on global mycology, designed to enable efficient discovery, analysis, and application of fungal science.

The platform incorporates advanced artificial intelligence tools to assist researchers, growers, product developers, and scientists in identifying relevant insights and accelerating the practical application of mycological research. Early testing indicates meaningful improvements in research efficiency and data accessibility compared to traditional methods.

MycoLabX combines this proprietary data and AI capability with its broader biomaterials and applied fungal biotechnology initiatives, creating a unified ecosystem intended to support innovation, product development, and commercialization.

Management believes this integrated approach positions MycoLabX to participate in multiple high-growth sectors, including healthcare, sustainable materials, agriculture, environmental applications, and industrial biotechnology.

Strategic Transaction Review
Mushrooms Inc. and SecurCapital Corp have worked cooperatively over recent months to evaluate a potential strategic transaction intended to establish a public operating platform for SecurCapital. During this process, the companies reviewed transaction structure, documentation, and strategic objectives associated with the proposed transaction.

Following recent advancements within the MycoLabX platform, including key technical validation milestones and platform progress, Mushrooms Inc. conducted a reassessment of its strategic positioning and long-term objectives. These developments have materially strengthened the company’s standalone position and strategic flexibility.

Both parties conducted the review process in good faith and mutually agreed that the originally contemplated transaction structure is being reevaluated and may be modified to better align with the company’s current strategic position and forward trajectory in light of recent developments within the MycoLabX platform.

The companies are issuing this update to reflect the recent MycoLabX milestones while maintaining a constructive relationship and leaving the door open for potential collaboration between the companies in the future.

As a result of these developments, the parties are not proceeding under the originally contemplated structure at this time and are instead evaluating alternative structures and strategic opportunities, that align with the company’s evolving strategic position.

Forward Strategy
Mushrooms Inc. will continue advancing development of the MycoLabX platform, including next phase testing of its infection-detection biomaterials and the launch of the MycoLab.ai research platform.

To support these next-stage development activities, the company is actively evaluating strategic funding opportunities to accelerate validation, scale testing, and advance the biomaterials platform toward commercialization.

Management believes these developments significantly strengthen the company’s position in emerging mycelium-based biomaterials, biomedical sensing technologies, and fungal biotechnology more broadly. The company believes the recent technical validation and progress within the MycoLabX platform create new opportunities to pursue strategic partnerships, research collaborations, and investment aligned with the expanded potential of the platform.

Mushrooms Inc. appreciates the constructive engagement and cooperation of SecurCapital throughout the evaluation process and values the collaborative discussions that have taken place. The company looks forward to potential opportunities to work together in the future and continues to explore strategic alternatives that may enhance shareholder value as both organizations continue advancing their respective strategic initiatives.

Further updates will be provided as developments occur.

Investor Interest
In connection with its continued development and upcoming validation initiatives, the Company is evaluating opportunities to engage with accredited investors interested in participating in the next phase of MycoLabX’s growth.

This potential financing is intended to support further product development, scale-up of biomaterials production, and advancement toward clinical and institutional validation, including planned collaboration efforts.

Accredited investors who are interested in learning more about this opportunity may request additional information by contacting the Company directly.

Breakthrough developments raise valuation - https://www.otcmarkets.com/stock/MSRM/news/Mushrooms-Inc-OTC-MSRM-Achieves-Proof-of-Concept-for-MycoLabX-Infection-Detection-Technology-and-Provides-Strategic-Upda?id=514822

Those are pretty much the same things I was told.
Well its an established business. already generating revenue, ready for growth.
I guess I will hold a chuck and see how it shakes out.

She told me ,. I would be replaced as CEO and it would move from biotech to logistics.
Just like yourself i have been here awhile . So lets see what happens .

Market cap right now extrapolated to just the unrestricted shares is under $200,000...measly amount for https://www.securcapital.com/. SecurCapital’s portfolio companies currently generate approximately $10 million in portfolio-percentage trailing twelve-month revenue. In other words maybe we should buy a chunk at this bottom pps and lean back

So you messaged with Kimberly? Does she plan to stay in mushroom business with a different ticker btw? Not that it matters for MSRM anymore

We will see , not really happy at this point

I Agree with you , now after e-mailing with the company , i don't see a good path going down the road . They may surprise us , but I am not as bullish as i once was .

Interesting turn of events. It will be interesting to see how the SS shakes out. Maybe it will lean more to the restricted share side. Its a pretty clean shell?

Agreed , was looking forward to seeing mushrooms inc take off , been here a while . Not sure what they plan on doing with it , they seemed optimistic 6 months ago

Per se a good merger. Still frustrated that the Mushroom Business has not panned out. Now its more of a play for me than investment...still, there is money to be made :)

Great news Yesterday . I hit Grok with a question about what MSRM is worth Per share , and this is what AI came up withSmall logistics or supply-chain finance plays (especially OTC or early-stage) typically trade at low multiples because of thin margins, execution risks, competition, and lack of scale. Realistic ranges:Conservative (0.5x revenue): Market cap ~$5M ? price ˜ $0.11 per share
(Common for unprofitable or low-margin ops in this space—think basic freight forwarding without big moats.)
Fair/moderate (1x revenue): Market cap ~$10M ? price ˜ $0.22 per share
(If they show steady revenue, some profitability path, and growth via acquisitions in airfreight/Asia as mentioned.)
Optimistic (1.5–2x revenue): Market cap $15M–$20M ? price ˜ $0.33–$0.44 per share
(If the portfolio companies scale, margins improve, or market gets hyped on the pivot—rare in OTC without catalysts like profitability or uplisting.)

These are pre-dilution estimates. If the deal adds, say, another 50–100M+ shares (typical in reverse mergers where the private side takes majority), the same $10M market cap would drop price to $0.05–$0.10 range. Upside would require the market to assign a higher multiple post-close (e.g., if revenue grows to $20M+ or they execute well).Bottom line: With current structure and $10M+ revenue locked in, $0.15–$0.30 feels like a reasonable "fair value" target in a best-case no-heavy-dilution scenario—way above current ~$0.03, but still penny territory with volatility. The no-dilution history is a plus, but this deal is dilution by design to bring in the revenue engine. If the ratio ends up shareholder-friendly (low issuance), it could pop hard on close; if heavy, it might reset lower before climbing.Keep watching for filings on the exchange details or any 8-K/6-K updates—that'll reveal the real dilution math. You still holding strong, or just watching the drama? What's your target exit if it hits certain levels?

Comparable OTC logistics valuations
Do your own Home work m but Im Happy to be a Shares holder

SS unchanged:
Outstanding Shares 39,944,916 01/22/2026
Restricted 24,060,304 01/22/2026
Unrestricted 15,884,612 01/22/2026

Outstanding Shares 39,944,916 11/20/2025
Restricted 24,060,304 11/20/2025
Unrestricted 15,884,612 11/20/2025

News Letter out !
I think they are trying really hard not to pump there Company , I find that interesting . Because the last time i Corresponded with the Company , they where dealing with Lawyers . Just my 2 Cents 🤗

Well by the looks of Friday's Buying , there about ready to Release there News letter and update what going on over Seas .The last time i E-mailed them , The said they were just waiting to cross the T's and Dot the I's ☺️

Outstanding Shares 39,944,916 11/20/2025
Restricted 24,060,304 11/20/2025
Unrestricted 15,884,612 11/20/2025

Outstanding Shares 39,944,916 10/06/2025
Restricted 26,560,304 10/06/2025
Unrestricted 13,384,612 10/06/2025

Outstanding Shares 39,435,760 09/29/2025
Restricted 26,445,148 09/29/2025
Unrestricted 12,990,612 09/29/2025

Spoke with the Company , and they said that the Monthly news letter is coming out and the update with there partner overseas is too.

I think the road is cleared...all shares converted from restricted to unrestricted likely have been sold AT NICE pps in blocks the last days. Lets get this steam engine going toward a dime once again....slowly but steadily.

I agree. Just would like to see all these converted shares sold already before I again buy more (I used to have 600k but now only 260k). Like today the 280k EOD were likely from that one person.

They have done well with the SS so far. I don't think a decent revenue stream is far off. They still hold a lot of my interest.

So that is an increase of 2.M unrestricted shares in three weeks...all converted from restricted (no change in OS). They have not been sold yet (but on a good note: whoever owns them does not want to dump...there are some 400k on the ask around 0.024 now) !

Outstanding Shares 39,944,916 10/06/2025
Restricted 26,560,304 10/06/2025
Unrestricted 13,384,612 10/06/2025

Outstanding Shares 39,944,916 10/30/2025
Restricted 24,060,304 10/30/2025
Unrestricted 15,884,612 10/30/2025

Share Structure
Market Cap Market Cap
838,843
10/30/2025
Authorized Shares
400,000,000
10/30/2025
Outstanding Shares
39,944,916
10/30/2025
Restricted
24,060,304
10/30/2025
Unrestricted
15,884,612
10/30/2025
Held at DTC
12,533,411
10/30/2025
Float Float
7,848,614

Excellent...in the last 3 weeks above 300K were traded. The SS has NOT changed incl. no move from restricted to unrestricted. It is safe to assume that the director has completed the announced sale. Overall given the market potential for mushroom based products incl. pharmaceutics, fabrics, construction materials, and so on PLUS various products by the company already being developed and others for sale by retailers I will now start to accumulate big (currently have 300k here).

Outstanding Shares 39,944,916 10/27/2025
Restricted 26,560,304 10/27/2025
Unrestricted 13,384,612 10/27/2025
Held at DTC 12,533,411 10/27/2025

So far 509.156 shares were added to the OS this week but have not hit the market yet (see volume in the last days = none; in the last 10 days = under 100k) and the director only announced 394.000 to be sold. Am waiting for their sale.
Outstanding Shares 39,944,916 10/06/2025
Restricted 26,560,304 10/06/2025
Unrestricted 13,384,612 10/06/2025

Outstanding Shares 39,435,760 09/29/2025
Restricted 26,445,148 09/29/2025
Unrestricted 12,990,612 09/29/2025

I think this month is going to be very Exciting , With the partner in Germany preparing a full October update on there next-generation of smart bandages ☺️

this company is such a joke! can we please get a new management team!!

394K shares to be sold starting monday by director so lets watch SS changes (resp restricted to unrestricted) closely but also keep in mind that the director holds already unrestricted shares and the float is around 8M

I do expect a pps retreat but not too violent...in any case I will accumulate more (freebies). For the past 2 years at any given time I had ~100k to 500k shares. Right now just 160k so I'd love to grab a few hundred k's in the low 01s again.

Outstanding Shares 39,435,760 09/25/2025
Restricted 26,445,148 09/25/2025
Unrestricted 12,990,612 09/25/2025

Ouch. The sale of common shares will start monday. Thats like the volume of like the whole last month alltogether.

Get ready for the dip to accumulate more shares, since Steinberg will sell 394k shares around 9/29. The 10 day average volume is just ~20 so take notice/watch (without worry since its explained/declared beforehand)

This Company will be A Force in the Future . They have kept there word ,keeping The Share Structure low , And once they start producing there products and Creating more Revenue , we will see the stock price move .

Newsletter full of good stuff. Things are happening.

Funding via Grant & Funding Pathways: SPOKE / ARPA-H Engagement
"we are not yet a listed member, our grant writing team remains in direct contact with SPOKE leadership and will continue efforts to integrate into this powerful funding and collaboration ecosystem."

"We’re optimistic about future participation, and in the meantime, our internal funding runway remains intact—with next-stage funding opportunities expected to open once we publish new technical data from Germany."

MYCOLabX bandages
"Our research partner in Germany is preparing a full October update on our next-generation smart bandage—a patent-pending technology"

Patent timeline
"We’re also awaiting feedback on our initial patent filing, with a decision expected in late Q4 2025 or early 2026"

News Letter Coming out ! I heard it from the Top . 🙂

Could someone Delete this post and my last one ? Our company is not making Chocolate bars at this time . I dont know how some other Mushroom company got a Hold of my E-Mail address , Thanks

Did anyone else receive an E-mail about there New Chocolate Mushroom Bars
Looks like the Company is Doing some Marketing :)

Take a bite, sit back, and let the good times roll
Feel Awesome, Like Really Awesome .. CLICK HERE !!

Insider Dumping - check out the Form 144 Filings - this was for consulting work? back in 2021 - Interesting
https://www.otcmarkets.com/filing/html?id=18514367&guid=udE-k61eNbcHJth
https://www.otcmarkets.com/filing/html?id=17694634&guid=udE-k61eNbcHJth

Unfortunately L2 looks the weakest since two months ago.

Potential for gains here,it seems?

I agree. It needs incredible patience, however. I am looking at years rather months.

News letter out ! I feel that this Stock is like a Barrel of Gunpower , with Only 26,445,148 Restricted shares and , Unrestricted: 12,990,612 shares . As soon as we get a update on Revenue or a Order for there Bandages and or other Projects that they are working on . BOOM ! This is just a Bomb waiting to go off .

Hello my fellow investor's . The company is working hard on multiple fronts , Thats what I was Told , And they are also working on the monthly news letter ,

After reading the blob post about FDA AI fast track approval, does anyone know if or when the filing takes place?


"Final Word
The FDA’s strategic push into AI-assisted review isn’t just internal optimization—it’s a paradigm shift that benefits innovators like Mushrooms Inc. and MYCOLabX. As we file a clear and concise 510(k) (or De Novo) with robust data, we could launch our bandage well within a year from filing—leaving competitors behind."

I see that the blogs have started up again, the monthly newsletters are back to being released monthly, there was a news release. Sounds like management is taking an interest in MSRM again.

What’s next ?

Outstanding Shares 39,435,760 06/14/2025
Restricted 26,445,148 06/14/2025
Unrestricted 12,990,612 06/14/2025

Mushrooms Inc.
@MushroomsInc
·
Jun 4
$MSRM Update:
MYCOLabX joins Mushrooms Inc. with no new shares issued — ZERO dilution.
MYCOLabX tech was originally developed under MSRM, making this consolidation a smart, shareholder-first move.
Access + innovation + integrity.
#Mycology #InvestSmart

Look for an update on share structure, post merger on x. That should be interesting.

Interim Financial Report - Form 8-K – Acquisition of MYCOLabX Inc. and Request to Remove Shell Risk
https://www.otcmarkets.com/file/company/financial-report/468720/content

no gave up awhile ago